Filing Flows › BioCorRx (BICX) › R&D spending
BioCorRx (BICX) R&D spending by quarter
BioCorRx's R&D spending was $712K in Q2 2026 (second quarter 2026), +102% from Q1 2026. Over the last 5 quarters it ranged from $162K (Q1 2025) to $1.0M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $712K | +102% | +140% |
| Q1 2026 | $352K | -65% | +118% |
| Q3 2025 | $1.0M | +238% | — |
| Q2 2025 | $297K | +83% | — |
| Q1 2025 | $162K | — | — |
Q2 2026 at a glance
BioCorRx, Q2 2026: revenue $88K (-51% year over year), net loss $1.0M, operating cash flow −$440K. The chart follows the revenue to costs, profit and cash.
Questions
What is BioCorRx's R&D spending?
BioCorRx's R&D spending was $712K in Q2 2026 (second quarter 2026), +102% from Q1 2026.
How has BioCorRx's R&D spending changed?
Over the last 5 quarters it ranged from $162K (Q1 2025) to $1.0M (Q3 2025).